Oxford researchers started new trial on the use of anti-TNF to treat Covid-19 in care homes
On Sept. 30, 2020, University of Oxford researchers announced they had begun a new study to explore the…
National Science Foundation funded more than 80 startups to address COVID-19 challenges
On Sept. 30, 2020, the National Science Foundation (NSF) announced that it had funded more than 80 startups…
WHO welcomed nearly $1 billion in pledges to bolster access to tests, treatments and vaccines to end COVID-19
On Sept. 30, 2020, the United Nations and its partners announced that nearly $1 billion in financing was…
BioNTech and Pfizer announced Nature publication of German phase 1/2 study data from mRNA-based vaccine candidate against SARS-CoV-2
On Sept. 30, 2020, Pfizer and BioNTech announced that preliminary, peer-reviewed data from their ongoing German Phase 1/2…
CureVac Initiated phase 2a clinical trial of COVID-19 vaccine candidate
On Sept. 29, 2020, CureVac announced that the first participant has been dosed in a Phase 2a clinical…
Increased COVID-19 cases reported in US among adults aged 18ﾖ22 years
On Sept. 29, 2020, the CDC reported that during Aug. 2ﾖSept. 5, 2020, weekly COVID-19 cases among persons…
Computer-designed proteins may protect against coronavirus
On Sept. 29, 2020, the NIH announed that researchers had designed ﾓminiproteinsﾔ that bound tightly to the SARS-CoV-2…
Serum Institute to produce additional 100 million Covid-19 vaccine doses for India and low-and middle-income countries
On Sept. 29, 2020, a further collaboration among the Serum Institute of India (SII), Gavi and the Bill…
REGN-COV2 antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients
On Sept. 29, 2020, Regeneron announced the first data from a descriptive analysis of a seamless Phase 1/2/3…
Windtree announced FDA acceptance of IND application for phase 2 clinical trial studying KL4 Surfactant in acute lung injury in adults with COVID-19
On Sept. 29, 2020, Windtree Therapeutics announced that FDA had accepted its Investigational New Drug application for a…
Immunic announced results from interim safety analysis from ongoing phase 2 CALVID-1 trial of IMU-838 in patients with COVID-19
On Sept. 28, 2020, Immunic announced the results of a pre-planned interim safety analysis and a recruitment update…
Eiger announced results of investigator sponsored study in outpatients with mild and uncomplicated COVID-19
On Sept. 28, 2020, Eiger BioPharmaceuticals announced results of an investigator sponsored study of Peginterferon Lambda-1a (Lambda) in…
DOD and HHS awarded $20 million contract to On Demand Pharmaceuticals to develop critical pharmaceutical ingredients
On Sept. 28, 2020, the U.S. Departments of Defense and Health and Human Services signed a $20 million…
ViroVax licensed adjuvant to be used in India’s first COVID-19 vaccine in human trials
On Sept. 28 2020, ViroVax announced that it had licensed its adjuvant, Alhydroxiquim-II, to Bharat Biotech International, an…
NIH-funded study shed light on abnormal neural function in rare genetic disorder
On Sept. 28, 2020, a genetic study identified neuronal abnormalities in the electrical activity of cortical cells derived…
About 14% of cerebral palsy cases may be tied to brain wiring genes
On Sept. 28, 2020, in an article published in Nature Genetics, researchers confirmed that about 14% of all…
Regular COVID-19 testing for groups most likely to spread the virus more efficient, cost-effective than random testing
On Sept. 28, 2020, as COVID-19 infections began to rise again, a novel testing strategy was proposed by…
Hologic granted FDA Emergency Use Authorization for asymptomatic COVID-19 testing with Panther Fusion SARS-CoV-2 assay
On Sept. 28, 2020, Hologic announced that its Panther Fusionﾮ SARS-CoV-2 assay had received Emergency Use Authorization (EUA)…
OpGen announced completion of study collaboration with Karolinska Institutet on bacterial co-infections in COVID-19 pneumonia patients
On Sept. 28, 2020, OpGen announced the successful completion of the clinical study between its subsidiary, Curetis, and…
Evaluation of LamPORE rapid tests for Covid-19 showed high levels of diagnostic sensitivity
On Sept. 25, 2020, scientists from the University of Oxfordﾒs Nuffield Department of Medicine published their evaluation of…
CDC’s ACIP recommended routine vaccination with a quadrivalent meningococcal conjugate vaccine for adolescents aged 11 or 12 years, with a booster dose at age 16 years.
On Sept. 25, 2020, the Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination with a quadrivalent meningococcal…
Scientists discovered genetic and immunologic underpinnings of some cases of severe COVID-19
On Sept. 24, 2020, new findings reported by scientists at the National Institutes of Health and their collaborators…
Human heart mapped cell by cell
On Sept. 24, 2020, a team of scientists announced they had created the first atlas of human heart…
FDA took actions to help lower US prescription drug prices
On Sept. 24, 2020, the U.S. Department of Health and Human Services and the U.S. Food and Drug…
Lumen Bioscience awarded Federal grant to rapidly develop antibody-based Covid-19 therapeutic
On Sept. 24, 2020, Lumen Bioscience and the US Army Medical Research and Development Command, announced an agreement…
FDA authorized first point-of-care antibody test for COVID-19
On Sept. 23, 2020, the FDA issued an emergency use authorization (EUA) for the first serology (antibody) point-of-care…
US Cruise ship no sail order extended through October 31, 2020
On Sept. 23, 2020, the CDC announced the extension of a No Sail Order for cruise ships through…
CDC provided $200 million to jurisdictions for COVID-19 vaccine preparedness
On Sept. 23, 2020, the CDC awarded $200 million to 64 jurisdictions through the existing Immunizations and Vaccines…
Humanigen announced Thermo Fisher partnership to expand manufacturing for COVID-19 therapeutic candidate Lenzilumab
On Sept. 23, 2020, Humanigen announced a strategic collaboration with Thermo Fisher Scientific to expand the manufacturing capacity…
Johnson & Johnson initiated pivotal global phase 3 clinical trial of Janssen’s COVID-19 vaccine candidate
On Sept. 23, 2020, Johnson & Johnson announced the launch of its large-scale, pivotal, multi-country Phase 3 trial…